|
gptkbp:instanceOf
|
gptkb:drug
renin inhibitor
|
|
gptkbp:approvalYear
|
2007
|
|
gptkbp:ATCCode
|
C09XA02
|
|
gptkbp:bioavailability
|
2.5%
|
|
gptkbp:brand
|
Rasilez
Tekturna
|
|
gptkbp:CASNumber
|
173334-57-1
|
|
gptkbp:category
|
antihypertensive agent
renin–angiotensin system inhibitor
|
|
gptkbp:contraindication
|
pregnancy
concomitant use with ACE inhibitors in diabetes
|
|
gptkbp:developer
|
gptkb:Novartis
|
|
gptkbp:discoveredBy
|
gptkb:Novartis
|
|
gptkbp:eliminationHalfLife
|
24 hours
|
|
gptkbp:excretion
|
feces
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:hasMolecularFormula
|
C30H53N3O6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
aliskiren
|
|
gptkbp:IUPACName
|
(2S,4S,5S,7S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]octanamide
|
|
gptkbp:KEGGID
|
D07454
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
direct renin inhibition
|
|
gptkbp:MeSH_ID
|
D000068879
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
47-51%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
4591676
5492044
DB01258
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
hyperkalemia
angioedema
|
|
gptkbp:UNII
|
8C2K2VUD7I
|
|
gptkbp:usedFor
|
hypertension
|
|
gptkbp:bfsParent
|
gptkb:valsartan
gptkb:sacubitril/valsartan
|
|
gptkbp:bfsLayer
|
6
|